ASXL1 and myelodysplastic syndrome: To better stratify the MDS patients into different risk groups, an integrated scoring system incorporating seven prognostic markers, including age, IPSS-R, and mutations of CBL, IDH2, DNMT3A, ASXL1, and TP53, into survival analysis was formulated.